文献类型：期刊文献

英文题名：Elucidating Astragaloside IV's Anti-Glioma Action via Network Pharmacology, Molecular Docking, and Experimental Evidence for PI3K/AKT Pathway Inhibition

作者：Wang, Ting[1];Han, Jing[2];Su, Rong[3,4];Wang, Zhuanxiong[3,4];Qiu, Shuping[3,4];Jing, Zhe[3,4];Gao, Xiaoqiang[5];Li, Hailong[2,3,4]

第一作者：王婷

通信作者：Li, HL[1];Li, HL[2];Li, HL[3];Gao, XQ[4]

机构：[1]Gansu Univ Chinese Med, Affiliated Hosp, Lab Clin Med, Lanzhou 730000, Peoples R China;[2]Gansu Univ Tradit Chinese Med, Affiliated Hosp, Dept Res Management, Lanzhou 730000, Peoples R China;[3]Gansu Res Ctr Tradit Chinese Med, Gansu Key Lab Pharmacol & Toxicol Tradit Chinese M, Lanzhou 730000, Peoples R China;[4]Gansu Univ Chinese Med, Clin Med Coll 1, Lanzhou 730000, Peoples R China;[5]Changchun Univ Tradit Chinese Med, Affiliated Dingxi Hosp, Hlth Examinat Ctr, Dingxi 743000, Peoples R China

第一机构：甘肃中医药大学第二附属医院

通信机构：[1]corresponding author), Gansu Univ Tradit Chinese Med, Affiliated Hosp, Dept Res Management, Lanzhou 730000, Peoples R China;[2]corresponding author), Gansu Res Ctr Tradit Chinese Med, Gansu Key Lab Pharmacol & Toxicol Tradit Chinese M, Lanzhou 730000, Peoples R China;[3]corresponding author), Gansu Univ Chinese Med, Clin Med Coll 1, Lanzhou 730000, Peoples R China;[4]corresponding author), Changchun Univ Tradit Chinese Med, Affiliated Dingxi Hosp, Hlth Examinat Ctr, Dingxi 743000, Peoples R China.|[10735]甘肃中医药大学;[10735b845793de6ae2b30]甘肃中医药大学第二附属医院;

年份：2025

卷号：14

期号：9

起止页码：23

外文期刊名：JOURNAL OF PIONEERING MEDICAL SCIENCES

收录：WOS:【ESCI(收录号:WOS:001629892600004)】；

基金：This paper was supported by Open Project of Gansu Provincial Traditional Chinese Medicine Research Center (zyzx-2020-04); Guiding Project of Lanzhou Science and Technology Bureau (2022-5-118).

语种：英文

外文关键词：Astragaloside IV; Glioma; PI3K/AKT Pathway; Molecular Docking

摘要：Objective: To investigate astragaloside IV's (AS-IV) anti-glioma effects and mechanisms. Methods: Potential ASIV targets were screened using SwissTarget, Super PRED, and PharmMapper databases. Glioma-related targets were identified from GeneCards, OMIM, and TTD. Intersection genes underwent Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. Anti-glioma mechanisms were investigated using A172 and U251 glioma cell lines. Cells were treated with AS-IV at 20, 30, or 50 mg/mL. MTT assessed proliferation. Cell scratch and transwell assays evaluated invasion. Flow cytometry analyzed cell cycle distribution and apoptosis. Western blot measured expression of cell cycle, apoptosis, epithelial-mesenchymal transition, and PI3K-AKT pathway-related genes. Results: Network pharmacology and molecular docking predicted AS-IV anti-glioma targets were associated with the PI3K/AKT pathway. AS-IV inhibited A172 and U251 cell proliferation and invasion dose- and time-dependently. It arrested the cell cycle in G0/G1 phase and induced apoptosis. AS-IV upregulated P21, Bax, and E-cadherin expression while downregulating CDK4, CDK6, Bcl-2, Vimentin, PPI3K, and P-AKT. Conclusion: AS-IV exhibits anti-tumor effects against glioma cells, potentially by inhibiting the PI3K/AKT signaling pathway. This leads to apoptosis induction, proliferation suppression, cell cycle arrest, and invasion inhibition.